Back to News
Market Impact: 0.35
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
Source: globenewswire.com
Healthcare & BiotechCompany FundamentalsTechnology & InnovationAnalyst Insights
Teva reported positive Phase 2a results for TEV '408, demonstrating significant prevention of gluten-induced intestinal damage in celiac disease. The clinical readout supports further development potential for an unmet-need therapeutic area, which is likely to be viewed favorably by investors and analysts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
TEVA0.60
More News
- Inside Fortescue’s billion-dollar bet to decarbonize mining—and help rebuild Ukraine
- Wall Street’s Nasdaq hits all-time high as AI frenzy gathers pace
- This oil giant has lagged its leading rivals through two energy crises. Now one Wall Street giant says it’s time to buy.
- Sullivan: Wall Street admits it doesn't know where oil is headed. There's one stock they do agree on
- Data-Center Bet Makes ESDS One of India’s Best New Listings
- UBS initiates Hut 8 Mining stock with buy rating on data center growth